S1 Biopharma downsizes IPO; Medgenics raising $21M;

@FierceBiotech: Woodford's investment strategy may help change the global biotech scene. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fledgling biotech upstart blends cutting-edge cancer immunotherapy strategies -- BeneVir. Article | Follow @JohnCFierce

@DamianFierce: It's almost as if Italian authorities don't care about biotech traders. More | Follow @DamianFierce

> New York-based S1 Biopharma has whittled down its IPO plans and now expects to offer 1.8 million shares at $12 to $14 a share. The biotech is working on a therapy for female sexual dysfunction. Story

> Philadelphia-based Medgenics ($MEDG) priced 5,125,000 shares in its underwritten public offering at $4.10 per share. The company plans to raise $21 million. Release

Medical Device News

@FierceMedDev: Congress considering bill to limit FDA regulation of EHRs, clinical decision support software. Story | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedDev: From FierceDrugDelivery: Survey raises the question: Do patients really know how to use drug delivery devices? Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: LabCorp and CareDx call it quits on partnership to develop lupus test. FierceDiagnostics story | Follow @EmilyWFierce

> Opponents of FDA's LDT regulations lawyer up, get in combat mode. Story

> WSJ: Ankle replacements look to be the next thing. More

> Strategic investors LabCorp, Envision put $15M into remote patient monitoring startup Vivify. Article

Pharma News

@FiercePharma: Merck KGaA to power India plant with coconut and cashew shells. Story | Follow @FiercePharma

@CarlyHFierce: AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. More | Follow @CarlyHFierce

> Who are the stars of personalized meds? Roche, Novartis and J&J. More

> Sanofi's pre-game show on Afrezza has MannKind followers chattering. Item

> Odds for a Pfizer-AZ matchup? All over the map, if you listen to analysts. Article

Drug Delivery News

> RNAi specialist Arrowhead reports loss of $58.7M in FY 2014. Item

> Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle. Report

> 'Hybrid' delivery vehicle gives DNA vaccines new potential. News

> Survey raises the question: Do patients really know how to use drug delivery devices? More

> Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's. Article

Diagnostics News

> Curetis nabs $18M to support European Dx rollout, U.S. trial, possible IPO. News

> Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article

> Indian startup develops low-cost, portable Dx for developing countries. Story

> LabCorp and CareDx call it quits on partnership to develop lupus test. Report

> Illumina teams up with Broad Institute, USAID for Ebola tracking. Item

Pharma Marketing News

> Who are the stars of personalized medicine? Roche, Novartis and J&J. Article

> From GPS inhalers to Jawbone data-gathering, some digital pharma inspiration. Story

> MannKind fans and critics line up for Sanofi's Afrezza pre-game show. More

> Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push. Story

> AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.